Latest Laquinimod Stories

2013-11-30 23:03:24

MarketReportsOnline.com offers “Global Multiple Sclerosis Market: Trends & Opportunities (2013-18)” research that analyzes the global market sizing and growth of multiple sclerosis in

2013-07-14 23:00:54

Transparency Market Research add new "Multiple Sclerosis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2012 - 2018" market research report to its

2011-12-08 07:57:27

Save the neurons! A new study suggests laquinimod triggers immune cells within the central nervous system produce and release brain-derived neurotrophic factor, BDNF, contributing to the repair or survival of neurons; therefore limiting brain damage.

2011-12-06 11:21:42

Laquinimod is an orally available synthetic compound that has been successfully evaluated in phase II/III clinical studies for the treatment of relapsing-remitting multiple sclerosis (RRMS).

2011-06-28 00:00:33

This report provides perspective on the MS landscape in light of Merck Serono’s decision to discontinue development and marketing of cladribine for MS. Scottsdale, AZ (PRWEB) June 27, 2011 MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Multiple Sclerosis,” designed to provide critical strategic insight for pharma and biotech companies...

2011-04-15 08:14:38

The drug laquinimod reduced the number of instances in relapses for individuals with multiple sclerosis (MS) in a long-term, phase III clinical study involving 1,106 participants with relapsing-remitting MS in 24 countries.

2008-11-06 03:00:20

Lund, Sweden, November 6, 2008 - Active Biotech (NASDAQ OMX Nordic: ACTI) is scheduled to present at the Rodman & Renshaw 10th Annual Healthcare Conference on Tuesday, November 11 at the New York Palace Hotel in New York City, US.

2008-10-28 09:00:07

Active Biotech (NASDAQ OMX Nordic: ACTI) has presented data regarding the 57-57 project at the American College of Rheumatology (ACR) Annual Scientific Meeting, a premier event for specialists in the field of rheumatology, held in San Francisco October 24-29*.

2008-10-17 03:00:16

Lund, Sweden, October 17, 2008 - Active Biotech AB's (NASDAQ OMX Nordic: ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) today announce information regarding the candidate drug RhuDex(R) for the treatment of rheumatoid arthritis.

2008-09-19 12:00:36

Teva Pharmaceutical Industries has reported new data from the extension phase of oral laquinimod in relapsing-remitting multiple sclerosis, which demonstrated a significant reduction in the mean number of gadolinium-enhancing lesions in both patients who switched from placebo to laquinimod and patients who continued with their initial laquinimod dose.

Word of the Day
  • A serpent whose bite was fabled to produce intense thirst.
The word 'dipsas' comes from a Greek word meaning 'thirst'.